TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26361391

Group type: EXPERIMENTAL
Intervention: 0.8 mm slice reconstruction
Number of subjects: 50

Group type: COMPARATOR
Intervention: 4.8 mm slice reconstruction
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thicker slices with AIF and motion correction based on thin slices
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thin slice reconstruction
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thick slice reconstruction
Number of subjects: 50
Study: 26361759

Group type: EXPERIMENTAL
Intervention: Integrative cuisine workshop program
Number of subjects: 86
Study: 26362511

Group type: EXPERIMENTAL
Intervention: Adaptive steps/day goals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static steps/day goals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate reinforcement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed reinforcement
Number of subjects: 0
Study: 26362616

Group type: EXPERIMENTAL
Intervention: One-stop-shop (OSS) concept using real-time in vivo reflectance confocal microscopy (RCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current standards of care in diagnosing and treating clinically suspected BCC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative patient satisfaction data
Number of subjects: 0
Study: 26362881

Group type: EXPERIMENTAL
Intervention: Ultrasound-based assessment of carotid artery plaque (CAP)
Number of subjects: 2216

Group type: EXPERIMENTAL
Intervention: Carotid intima-media thickness (CIMT)
Number of subjects: 2216

Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI)
Number of subjects: 2216

Group type: EXPERIMENTAL
Intervention: Presence of NCA and typical angina
Number of subjects: 2216

Group type: EXPERIMENTAL
Intervention: Atypical clinical presentation and lack of NCA
Number of subjects: 2216
Study: 26362903

Group type: EXPERIMENTAL
Intervention: Fingolimod treatment (1d)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fingolimod treatment (3mo)
Number of subjects: 27
Study: 26363331

Group type: EXPERIMENTAL
Intervention: EUS-guided ethanol lavage (EEL) with 80% ethanol
Number of subjects: 23
Study: 26363334

Group type: EXPERIMENTAL
Intervention: Colon Capsule Endoscopy (CCE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Small-Intestine Contrast Ultrasound (SICUS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Magnetic Resonance Enterography (MRE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ileocolonoscopy
Number of subjects: 40
Study: 26363342

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of autologous, unfractionated bone marrow
Number of subjects: 6
Study: 26363547

Group type: EXPERIMENTAL
Intervention: Biotin-labeled autologous neonatal red blood cells (BioRBC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Biotin-labeled allogeneic adult red blood cells (BioRBC)
Number of subjects: 15
Study: 26363548

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 22
Study: 26363834

Group type: EXPERIMENTAL
Intervention: Upstream-dominant lesions
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Downstream-dominant lesions
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Overall correlation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Pressure gradient, FFRCT, and wall shear stress
Number of subjects: 81

Group type: COMPARATOR
Intervention: Distribution of APS
Number of subjects: 81
Study: 26363838

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26363899

Group type: EXPERIMENTAL
Intervention: Inclacumab 0.3 mg/kg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Inclacumab 3.0 mg/kg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Inclacumab 20 mg/kg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Inclacumab (all doses)
Number of subjects: 62
Study: 26363929

Group type: EXPERIMENTAL
Intervention: Step-up FMT strategy
Number of subjects: 15
Study: 26364279

Group type: EXPERIMENTAL
Intervention: Powered exoskeleton (ReWalk) with Lofstrand crutches
Number of subjects: 12
Study: 26364679

Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 1353

Group type: COMPARATOR
Intervention: Surgery (control)
Number of subjects: 1353
Study: 26364690

Group type: COMPARATOR
Intervention: Mobile group (N=7)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Training group (N=16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (N=9)
Number of subjects: 32
Study: 26364966

Group type: EXPERIMENTAL
Intervention: Endoscopic clips used during EMR
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Endoscopic clips used during EMR for prophylaxis of bleeding
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Presence of residual clips
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Greater age
Number of subjects: 111
Study: 26364984

Group type: EXPERIMENTAL
Intervention: Oral Methadone (0.1 mg/kg per dose every 6 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimized dosing strategies based on simulated PK profiles
Number of subjects: 0
Study: 26365536

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 80
Study: 26366204

Group type: EXPERIMENTAL
Intervention: Short-term HRV test
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ewing's test
Number of subjects: 56
Study: 26366430

Group type: EXPERIMENTAL
Intervention: Maraviroc 600 mg twice daily
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 26366956

Group type: EXPERIMENTAL
Intervention: Management strategies proposed by authors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current guidelines
Number of subjects: 0
Study: 26367141

Group type: EXPERIMENTAL
Intervention: ShangRing circumcision
Number of subjects: 194
Study: 26367187

Group type: EXPERIMENTAL
Intervention: Voluntary Medical Male Circumcision (VMMC) using the Forceps Guided Method Under Local Anesthesia
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Voluntary Medical Male Circumcision (VMMC)
Number of subjects: 454
Study: 26367236

Group type: EXPERIMENTAL
Intervention: Treosulfan, etoposide and cyclophosphamide
Number of subjects: 50
Study: 26368663

Group type: EXPERIMENTAL
Intervention: Remifentanil in PD group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Remifentanil in NPD group
Number of subjects: 31
Study: 26369751

Group type: EXPERIMENTAL
Intervention: Normal left ventricular filling pressure (Group A)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Elevated left ventricular filling pressure (Group B)
Number of subjects: 57
Study: 26370823

Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 3116

Group type: COMPARATOR
Intervention: calcium-free balanced solution
Number of subjects: 3116
Study: 26370838

Group type: EXPERIMENTAL
Intervention: Afucosylated anti-BCMA monoclonal antibody conjugated with monomethyl auristatin F (GSK2857916)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor-expressing T cells targeting BCMA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26371148

Group type: EXPERIMENTAL
Intervention: Surgical excision (lumpectomy) without radiation
Number of subjects: 665
Study: 26371152

Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg once daily and Elbasvir 50 mg once daily coadministered with weight-based Ribavirin twice daily for 12 weeks
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Grazoprevir and Elbasvir with Ribavirin for 12 weeks
Number of subjects: 79
Study: 26371702

Group type: EXPERIMENTAL
Intervention: Active CPAP
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 3
Study: 26371816

Group type: EXPERIMENTAL
Intervention: Venoarterial extracorporeal membrane oxygenation (VA-ECMO)
Number of subjects: 0
Study: 26372191

Group type: EXPERIMENTAL
Intervention: Total percutaneous endovascular aortic repair (PEVAR) using large-diameter sheaths with thoracic, fenestrated, and branched stent grafts.
Number of subjects: 102
Study: 26372452

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) administered within 5 days after onset of illness
Number of subjects: 2304

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG) administered after 10 days
Number of subjects: 2304
Study: 26372465

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)/Vilanterol (VI) 100/25 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)/Vilanterol (VI) 200/25 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC)/Vilanterol (VI) 62.5/25 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 100 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 200 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC) 62.5 μg
Number of subjects: 0
Study: 26373291

Group type: EXPERIMENTAL
Intervention: Patients who would have been excluded from the ISCHEMIA trial (Group A)
Number of subjects: 3102

Group type: COMPARATOR
Intervention: Patients who did not meet the ISCHEMIA trial exclusion criteria (Group B)
Number of subjects: 3102
Study: 26373629

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2313
Study: 26374548

Group type: EXPERIMENTAL
Intervention: Mass spectrometry analysis of urine samples
Number of subjects: 600

Group type: COMPARATOR
Intervention: Biopsy
Number of subjects: 600
Study: 26374908

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) for younger (18-44 y)
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) for middle-aged (45-64 y)
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) for elderly (65-79 y)
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) for aged (≥ 80 y)
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: NIV use for cardiogenic pulmonary edema
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: NIV use with do-not-intubate order
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: NIV with do-not-intubate order for different age groups
Number of subjects: 1225
Study: 26375411

Group type: EXPERIMENTAL
Intervention: Computer-Delivered Brief Intervention (CBI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Counselor-Delivered Individual Brief Intervention (IBI)
Number of subjects: 12
Study: 26375437

Group type: EXPERIMENTAL
Intervention: Underwater EMR (UEMR) without submucosal injection
Number of subjects: 27
Study: 26375439

Group type: EXPERIMENTAL
Intervention: MET tyrosine kinase inhibitors and a monoclonal antibody targeting MET
Number of subjects: 230

Group type: COMPARATOR
Intervention: METex14del cases
Number of subjects: 230
Study: 26375589

Group type: EXPERIMENTAL
Intervention: Store-and-forward teledermatology referrals
Number of subjects: 391

Group type: COMPARATOR
Intervention: Conventional referrals
Number of subjects: 391
Study: 26375670

Group type: EXPERIMENTAL
Intervention: Rapa (1 mg) and HCQ (200 mg) twice daily for two weeks
Number of subjects: 10
Study: 26375808

Group type: EXPERIMENTAL
Intervention: Methylphenidate immediate-release (MPH-IR) treatment
Number of subjects: 171

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 171
Study: 26375845

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC of 5 intravenously every 21 days), Everolimus (5 mg orally once daily), Prednisone (5 mg orally twice daily)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC of 4 for subsequent patients after dose adjustment)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Positive nuclear phosphorylated AKT (pAKT) staining
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: mTOR inhibitor everolimus added to carboplatin
Number of subjects: 26
Study: 26376038

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) in PE patients without DVT
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Coronary artery disease in PE patients without DVT
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Permanent AF in individuals without DVT
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Paroxysmal AF in individuals with DVT
Number of subjects: 295

Group type: COMPARATOR
Intervention: Survival of PE patients with and without DVT
Number of subjects: 295

Group type: COMPARATOR
Intervention: Cost-relevant clinical outcome of PE patients with and without DVT
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: AF in PE patients
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Survival of AF in PE patients
Number of subjects: 295
Study: 26376348

Group type: EXPERIMENTAL
Intervention: Weight gain
Number of subjects: 27
Study: 26376436

Group type: EXPERIMENTAL
Intervention: cART supplemented with probiotics
Number of subjects: 20

Group type: COMPARATOR
Intervention: cART
Number of subjects: 20
Study: 26376459

Group type: EXPERIMENTAL
Intervention: IV-Erwinia (25,000 IU/m²/dose administered on Monday/Wednesday/Friday for 2 consecutive weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IV-Erwinia
Number of subjects: 30
Study: 26376647

Group type: EXPERIMENTAL
Intervention: Plasma protein classifier
Number of subjects: 475

Group type: COMPARATOR
Intervention: Clinical practices
Number of subjects: 475
Study: 26376939

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day until progression/discontinuation or commercial availability
Number of subjects: 906

Group type: COMPARATOR
Intervention: Overall population (not specified intervention)
Number of subjects: 906
Study: 26377024

Group type: EXPERIMENTAL
Intervention: SAGIT instrument
Number of subjects: 13
Study: 26377379

Group type: EXPERIMENTAL
Intervention: SCA1
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: SCA2
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: SCA3
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: SCA6
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: SCA1, SCA2, SCA3
Number of subjects: 462
Study: 26377415

Group type: COMPARATOR
Intervention: Clear lens
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4 mm optical zone lens
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5 mm optical zone lens
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5 mm and 4 mm optical zone lenses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All optical zone diameters
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reduced pigment-free optical zone diameters
Number of subjects: 30
Study: 26377597

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin monotherapy
Number of subjects: 27
Study: 26377635

Group type: EXPERIMENTAL
Intervention: Open surgery (60 patients); 78% abdominal fundoplication, 10% Belsey Mark IV, 8% laparotomic Collis-Nissen fundoplication, 3% Pearson operation
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (48 patients); 44% laparoscopic floppy Nissen, 56% left thoracoscopic Collis-laparoscopic Nissen
Number of subjects: 108
Study: 26379127

Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 86
Study: 26379163

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) as oral solution or capsule sprinkle plus didanosine and emtricitabine (FTC)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) as capsule sprinkle
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 37
Study: 26379282

Group type: EXPERIMENTAL
Intervention: Intravenous 5 mg/m2 romidepsin once weekly for 3 weeks while maintaining ART
Number of subjects: 6
Study: 26379437

Group type: EXPERIMENTAL
Intervention: Phosphocholine (PC) PC(O-12:0/2:0)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Phosphocholine (PC) PC(O-14:1/2:0)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Phosphocholine (PC) PC(O-17:3/2:0)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Phosphocholine (PC) PC(O-18:3/2:0)
Number of subjects: 26
Study: 26379759

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (150 ± 106 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 26
Study: 26380086

Group type: EXPERIMENTAL
Intervention: ipilimumab (10 mg/kg IV every 3 weeks, 2 doses)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Baseline IL-17 level
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Baseline TGF-β1 and IL-10 levels
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Week 6 cytokines
Number of subjects: 35
Study: 26380150

Group type: EXPERIMENTAL
Intervention: Ruxolitinib with concomitant ESA administration
Number of subjects: 146

Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 146
Study: 26380731

Group type: EXPERIMENTAL
Intervention: Nadroparin calcium BID (4,100 AxaIU q12h)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Nadroparin calcium QD (4,100 AxaIU qd + placebo qd)
Number of subjects: 111
Study: 26380993

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 24
Study: 26381120

Group type: EXPERIMENTAL
Intervention: Family planning services (FP)
Number of subjects: 1887

Group type: EXPERIMENTAL
Intervention: Dual use of FP
Number of subjects: 1887

Group type: EXPERIMENTAL
Intervention: Unintended pregnancies
Number of subjects: 1887

Group type: EXPERIMENTAL
Intervention: Short-acting contraceptives
Number of subjects: 1887
Study: 26381530

Group type: EXPERIMENTAL
Intervention: Everolimus (3mg/m²/day, titrated to target blood trough levels of 5-15ng/ml)
Number of subjects: 28
Study: 26381736

Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg) administered 0.5 hours before cangrelor discontinuation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg) administered 1 hour before cangrelor discontinuation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel administered immediately after cangrelor discontinuation
Number of subjects: 0
Study: 26382006

Group type: EXPERIMENTAL
Intervention: fMRI data acquisition during passive fixation with visual stimuli presented at various locations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contralateral and ipsilateral stimulus pairs with different textures and shapes
Number of subjects: 0
Study: 26382051

Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE) during EUS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Final diagnosis
Number of subjects: 15
Study: 26382589

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-TNF agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 26383952

Group type: EXPERIMENTAL
Intervention: Primary infection antisera
Number of subjects: 0
Study: 26384013

Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 2772
Study: 26384102

Group type: EXPERIMENTAL
Intervention: Semantic feature analysis
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Repeated attempts to name untreated items
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Provision of the names of untrained items
Number of subjects: 5
Study: 26384164

Group type: EXPERIMENTAL
Intervention: Human CD133(+) bone marrow-derived stem cells (BMDSCs) injected intrauterinely
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Human CD133(+) bone marrow-derived stem cells (BMDSCs) injected systemically through the tail vein
Number of subjects: 10
Study: 26384163

Group type: EXPERIMENTAL
Intervention: AMH levels throughout the menstrual cycle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mean AMH concentrations
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mean luteal AMH levels
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Number of antral follicles estimated from AMH levels
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AMH concentrations
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preovulatory AMH levels
Number of subjects: 40
Study: 26384204

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-generation TAVI devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAVI registries data
Number of subjects: 0
Study: 26384354

Group type: EXPERIMENTAL
Intervention: Carfilzomib, pomalidomide, and dexamethasone (CPD)
Number of subjects: 32
Study: 26384469

Group type: EXPERIMENTAL
Intervention: Status epilepticus with good outcome
Number of subjects: 47

Group type: COMPARATOR
Intervention: Status epilepticus with poor outcome
Number of subjects: 47
Study: 26384573

Group type: EXPERIMENTAL
Intervention: Chinese parent version of the Autism Spectrum Rating Scale (ASRS)
Number of subjects: 1836
Study: 26384710

Group type: EXPERIMENTAL
Intervention: Quality indicators for perioperative diabetes care
Number of subjects: 389
Study: 26384789

Group type: EXPERIMENTAL
Intervention: Lapatinib plus vinorelbine (lap+vin)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine (lap+cap)
Number of subjects: 112
Study: 26385385

Group type: EXPERIMENTAL
Intervention: Chemosensitivity test (CD-DST) using four different concentrations of 5-fluorouracil
Number of subjects: 206

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with S-1
Number of subjects: 206
Study: 26385402

Group type: EXPERIMENTAL
Intervention: Midfollicular serum SHBG concentrations
Number of subjects: 319
Study: 26385462

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor antagonist exendin 9-39 (during infusion)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (placebo) infusion
Number of subjects: 40
Study: 26386044

Group type: EXPERIMENTAL
Intervention: Biallelic mutations in KIAA0586
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fibroblasts from patients with Jeune-Joubert syndrome
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Rescue with full-length wild type KIAA0586
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: KIAA0586 RNA expression levels
Number of subjects: 6
Study: 26386667

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4030
Study: 26386794

Group type: EXPERIMENTAL
Intervention: Platelet function testing
Number of subjects: 10048

Group type: EXPERIMENTAL
Intervention: Pharmacogenomic testing
Number of subjects: 10048

Group type: EXPERIMENTAL
Intervention: Higher-potency adenosine diphosphate receptor inhibitors (prasugrel/ticagrelor)
Number of subjects: 10048
Study: 26387127

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 0
Study: 26387811

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 214